Research

• World leader in structure and fragment-based drug discovery
• Fully integrated structural biology with medicinal chemistry
• Excellent track record for innovation and delivery
• Collaborations with Novartis, Servier, Genentech and Lundbeck

Vernalis is a world leader in structure and fragment-based drug discovery, with an excellent track record for innovation and delivery of clinical candidates in a range of therapeutic areas. Our internal research is currently aimed at discovering novel anti-cancer therapies by targeting cancer metabolism and cancer-specific synthetic lethality relationships.